Department of Orthopaedics, Dongguk University Ilsan Hospital, Goyang, Republic of Korea.
Tissue Eng Part A. 2010 Mar;16(3):851-60. doi: 10.1089/ten.TEA.2009.0070.
This study tested the hypothesis that mitogen-activated protein kinase inhibitors suppress hypertrophy and enhance chondrogenesis during chondrogenesis of multipotent mesenchymal stromal cells (MSCs). The effects of PD98059 (an extracellular signal-regulated kinase-1/2 inhibitor) and SB203580 (a p38 inhibitor) were tested on bone marrow-derived MSCs (BMMSCs) and adipose tissue-derived MSCs (ATMSCs). In vitro pellet cultures were carried out using 2.5 x 10(5) MSCs in a chondrogenic medium containing 5 ng/mL of transforming growth factor-beta(2) (TGF-beta(2)) for BMMSCs, and 5 ng/mL of TGF-beta(2) and 100 ng/mL of bone morphogenetic protein-7 (BMP-7) for ATMSCs. From the 14th day of culture, the pellets were additionally treated with PD98059 or SB203580. After 14 more days of in vitro culture, pellets were harvested for analysis. PD98059 increased DNA content and glycosaminoglycan amount in BMMSCs and ATMSCs, whereas SB203580 had little effect. Collagen type I (COL1A1) mRNA decreased to almost a quarter in BMMSCs treated with PD98059. The mRNA levels of collagen type II (COL2A1) and SRY (sex determining region Y)-box 9 (SOX-9) increased several fold in both cells after PD98059 treatment, whereas SB203580 had only a slight effect. The gene expression of collagen type X (COL10A1) and runt-related transcription factor 2 (Runx-2) decreased by half after PD98059 treatment in BMMSCs, and decreased further in ATMSCs. SB203580 elevated COL10A1 and Runx-2 gene expression in both cell types. Safranin-O staining and immunohistochemistry generally mirrored findings from real-time PCR except for diminished expression of type I collagen in ATMSCS, and more pronounced decrease in type X collagen and Runx-2 in BMMSCs after PD98059 treatment. Our study demonstrated that PD98059 suppressed hypertrophy and promoted chondrogenesis of MSCs, and provides a ground for using them in cartilage tissue engineering.
本研究旨在检验丝裂原活化蛋白激酶抑制剂(MAPKIs)在多能间充质基质细胞(MSCs)软骨形成过程中抑制肥大和增强软骨形成的假说。通过检测 PD98059(ERK1/2 抑制剂)和 SB203580(p38 抑制剂)对骨髓来源的间充质基质细胞(BMMSCs)和脂肪组织来源的间充质基质细胞(ATMSCs)的作用,进行了体外微球培养。对于 BMMSCs,在含有 5ng/mL 转化生长因子-β2(TGF-β2)的软骨形成培养基中,用 2.5×10(5)个 MSC 进行微球培养,对于 ATMSCs,在含有 5ng/mL TGF-β2 和 100ng/mL 骨形态发生蛋白-7(BMP-7)的软骨形成培养基中进行微球培养。从培养的第 14 天开始,微球还接受 PD98059 或 SB203580 的处理。在体外培养 14 天后,收获微球进行分析。PD98059 增加了 BMMSCs 和 ATMSCs 的 DNA 含量和糖胺聚糖含量,而 SB203580 几乎没有效果。PD98059 处理后,BMMSCs 中的Ⅰ型胶原(COL1A1)mRNA 减少到几乎四分之一。PD98059 处理后,两种细胞中的Ⅱ型胶原(COL2A1)和性别决定区 Y 框 9(SOX-9)mRNA 水平增加了数倍,而 SB203580 仅有轻微作用。PD98059 处理后,BMMSCs 中的 COL10A1 和 runt 相关转录因子 2(Runx-2)基因表达减少一半,在 ATMSCs 中进一步减少。SB203580 提高了两种细胞类型的 COL10A1 和 Runx-2 基因表达。番红 O 染色和免疫组织化学通常与实时 PCR 的结果一致,除了 ATMSCs 中Ⅰ型胶原表达减少,以及 PD98059 处理后 BMMSCs 中 X 型胶原和 Runx-2 表达减少更明显。本研究表明 PD98059 抑制了 MSCs 的肥大并促进了其软骨形成,并为它们在软骨组织工程中的应用提供了依据。